XXXX in Sweden: incidence and clinical features.

@entity1 @entity573 @entity117 @entity439 @entity299
The incidence and clinical pattern of @entity1 with @entity573 in Sweden and the outcome of treatment with i.v. immunoglobulin (Sandoglobulin) and @entity117 were examined in a national prospective study over a 2-year period. Cases not referred to the study were identified by inquiry. Ninety-nine @entity1 were diagnosed as having @entity573 . The annual incidence rate was calculated to be 2.9 per 100,000 in @entity1 younger than 16 years of age and 6.2 per 100,000 in @entity1 younger than 5 years of age. The median age of our @entity1 was 2.2 years and the male-to-female ratio was 2.3:1. Cardiac ultrasonography revealed abnormalities in 33% of all @entity1 , and 14% of cases in the prospective study had pronounced abnormalities. In most cases (91%) treatment had a prompt effect on fever and morbidity in general, and side effects were mild. Two @entity1 , identified from the inquiry, died from rupture of an @entity439 in the coronary artery in the acute phase of the disease. The risk of @entity299 is obvious and emphasizes the importance of early diagnosis and treatment.
